INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,889,773 | -28.9% | 36,279 | -13.6% | 0.02% | -40.6% |
Q2 2023 | $2,657,920 | +13.9% | 41,976 | -16.3% | 0.03% | -36.0% |
Q3 2022 | $2,334,000 | +118.3% | 50,158 | +167.8% | 0.05% | +78.6% |
Q2 2022 | $1,069,000 | +53.6% | 18,727 | +0.3% | 0.03% | +154.5% |
Q3 2021 | $696,000 | +50.3% | 18,678 | -41.6% | 0.01% | -8.3% |
Q4 2017 | $463,000 | -51.1% | 31,965 | -46.7% | 0.01% | -50.0% |
Q3 2017 | $947,000 | -61.0% | 59,991 | -1.1% | 0.02% | -70.7% |
Q3 2015 | $2,428,000 | +567.0% | 60,637 | +203.2% | 0.08% | +446.7% |
Q1 2014 | $364,000 | – | 20,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |